Outset Medical, Inc. (OM)
NASDAQ: OM · IEX Real-Time Price · USD
3.870
-0.170 (-4.21%)
At close: Jul 19, 2024, 4:00 PM
3.880
+0.010 (0.26%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Outset Medical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Outset Medical stock have an average target of 5.30, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 36.95% from the current stock price of 3.87.
Analyst Consensus: Buy
* Price targets were last updated on Jun 21, 2024.
Analyst Ratings
The average analyst rating for Outset Medical stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold → Buy Upgrades $5 → $6 | Hold → Buy | Upgrades | $5 → $6 | +55.04% | Jun 21, 2024 |
| BTIG | BTIG | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +55.04% | Apr 8, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $14 → $6 | Buy → Hold | Downgrades | $14 → $6 | +55.04% | Jan 12, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $5.5 | Hold | Maintains | $5 → $5.5 | +42.12% | Dec 4, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $5 | Hold | Maintains | $19 → $5 | +29.20% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
150.80M
from 130.38M
Increased by 15.67%
Revenue Next Year
178.85M
from 150.80M
Increased by 18.60%
EPS This Year
-1.84
from -3.48
EPS Next Year
-1.21
from -1.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 156.2M | 187.3M | 224.0M | 254.8M | 299.4M |
| Avg | 150.8M | 178.9M | 213.2M | 248.9M | 293.7M |
| Low | 142.1M | 161.9M | 199.2M | 235.7M | 279.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.8% | 24.2% | 25.2% | 19.5% | 20.3% |
| Avg | 15.7% | 18.6% | 19.2% | 16.7% | 18.0% |
| Low | 9.0% | 7.4% | 11.4% | 10.6% | 12.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.80 | -0.59 | -0.21 | -0.43 | 0.09 |
| Avg | -1.84 | -1.21 | -0.95 | -0.43 | 0.09 |
| Low | -1.81 | -1.43 | -1.18 | -0.41 | 0.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.